Odyssey Therapeutics

Company snapshot

Odyssey Therapeutics is a biotech organization headquartered in San Ramon, USA. It trades on NYSE under ticker ODTX. Primary therapeutic focus areas include Moderately to Severely Active Ulcerative Colitis, Inflammatory Bowel Diseases, Ulcerative Colitis (UC), Traumatic Brain Injury (TBI). NovaPharmaNews links 4 clinical program(s), 2 drug profile(s), and 1 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (2), phase 1 (2).

• 2 approved product(s) across US/EU regulatory metadata.
• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Odyssey Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Odyssey Therapeutics.

1. Jun 8, 2026 Clinical update

   OD-07656-201 — Phase 2

2. May 23, 2026 Clinical update

   OD-07656 — Phase 2

3. May 23, 2026 Clinical update

   OD-07656 — Phase 1

4. May 23, 2026 Clinical update

   PRV-002 — Phase 1

5. Dec 11, 2007 Patent grant

   Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy

View all clinical trial activity →

• What is Odyssey Therapeutics?

  Odyssey Therapeutics is a biotech organization headquartered in San Ramon, USA. It trades on NYSE under ticker ODTX. Primary therapeutic focus areas include Moderately to Severely Active Ulcerative Colitis, Inflammatory Bowel Diseases, Ulcerative Colitis (UC), Traumatic Brain Inj

• Is Odyssey Therapeutics publicly traded?

  Yes. Odyssey Therapeutics is listed with ticker ODTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Odyssey Therapeutics develop or market?

  We link 6 drug profile(s) where Odyssey Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/odyssey-therapeutics#company-drugs.

• What are the latest developments for Odyssey Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Odyssey Therapeutics focus on?

  Odyssey Therapeutics focuses on Moderately to Severely Active Ulcerative Colitis, Inflammatory Bowel Diseases, Ulcerative Colitis (UC) based on our analysis of their pipeline programs and drug development activities.